Abstract
Tibotec (formerly Tibotec-Virco) is developing TMC-114 as a potential treatment for HIV-1 infection. In February 2001, TMC-126 was revealed as the series prototype, from which TMC-114 was developed. Because of its improved antiviral and superior pharmacokinetic properties, TMC-114 was selected for clinical development. Phase II trials of TMC-114 are underway.
MeSH terms
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / pharmacokinetics
-
Anti-HIV Agents / pharmacology*
-
Anti-HIV Agents / therapeutic use
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Darunavir
-
Humans
-
Patents as Topic
-
Randomized Controlled Trials as Topic
-
Structure-Activity Relationship
-
Sulfonamides / adverse effects
-
Sulfonamides / pharmacokinetics
-
Sulfonamides / pharmacology*
-
Sulfonamides / therapeutic use
Substances
-
Anti-HIV Agents
-
Sulfonamides
-
Darunavir